GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Valeo Pharma Inc (TSX:VPH) » Definitions » EV-to-EBITDA

Valeo Pharma (TSX:VPH) EV-to-EBITDA : -5.74 (As of May. 22, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Valeo Pharma EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Valeo Pharma's enterprise value is C$65.53 Mil. Valeo Pharma's EBITDA for the trailing twelve months (TTM) ended in Jan. 2024 was C$-11.42 Mil. Therefore, Valeo Pharma's EV-to-EBITDA for today is -5.74.

The historical rank and industry rank for Valeo Pharma's EV-to-EBITDA or its related term are showing as below:

TSX:VPH' s EV-to-EBITDA Range Over the Past 10 Years
Min: -30.8   Med: -6.16   Max: -3.11
Current: -5.73

During the past 7 years, the highest EV-to-EBITDA of Valeo Pharma was -3.11. The lowest was -30.80. And the median was -6.16.

TSX:VPH's EV-to-EBITDA is ranked worse than
100% of 711 companies
in the Drug Manufacturers industry
Industry Median: 14.89 vs TSX:VPH: -5.73

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-22), Valeo Pharma's stock price is C$0.095. Valeo Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jan. 2024 was C$-0.330. Therefore, Valeo Pharma's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Valeo Pharma EV-to-EBITDA Historical Data

The historical data trend for Valeo Pharma's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Valeo Pharma EV-to-EBITDA Chart

Valeo Pharma Annual Data
Trend Oct17 Oct18 Oct19 Oct20 Oct21 Oct22 Oct23
EV-to-EBITDA
Get a 7-Day Free Trial -4.74 -13.31 -5.79 -4.85 -6.32

Valeo Pharma Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -6.15 -6.15 -6.30 -6.32 -7.51

Competitive Comparison of Valeo Pharma's EV-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Valeo Pharma's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Valeo Pharma's EV-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Valeo Pharma's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Valeo Pharma's EV-to-EBITDA falls into.



Valeo Pharma EV-to-EBITDA Calculation

Valeo Pharma's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=65.533/-11.423
=-5.74

Valeo Pharma's current Enterprise Value is C$65.53 Mil.
Valeo Pharma's EBITDA for the trailing twelve months (TTM) ended in Jan. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-11.42 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Valeo Pharma  (TSX:VPH) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Valeo Pharma's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.095/-0.330
=At Loss

Valeo Pharma's share price for today is C$0.095.
Valeo Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jan. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.330.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Valeo Pharma EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Valeo Pharma's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Valeo Pharma (TSX:VPH) Business Description

Traded in Other Exchanges
Address
16667, Hymus Boulevard, Kirkland, QC, CAN, H9H 4R9
Valeo Pharma Inc is a Canadian specialty pharmaceutical company focused on acquiring either through acquisitions, in-licensing, or similar arrangements. The company operates in two divisions: Branded prescription products and Niche hospital injectable products. Its product portfolio includes medicines for Respiratory/Allergy, Ophthalmology, Neurology, and Oncology.
Executives
Luc Mainville Senior Officer

Valeo Pharma (TSX:VPH) Headlines

No Headlines